SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets: MNTR) is pleased to announce that it is providing equity funding to support Quantum Immunologics, Inc. (QI) to complete their FDA authorized Phase I/II trials on metastatic breast cancer, which are now underway (NCT00879489). QI holds exclusive license to patents that pertain to certain therapeutic and diagnostic applications of the Oncofetal Antigen (OFA), a universal marker found on all tested cancer lines but not found in normal tissues. The current QI clinical approach is to externally process and sensitize dendritic cells from the patient’s own blood to recognize the OFA in their breast cancers as a marker for diseased tissue. The sensitized dendritic cells are then re-injected into the patient to stimulate their body’s own immune system to attack the cancerous cells in an effort to eradicate or stabilize the patient’s disease. Dendreon (DNDN) utilizes a similar dendritic immunotherapy approach, but focuses on a prostate-specific protein, through its Provenge product.
